Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.55) by 7.27 percent. This is a 95.99 percent increase over losses of $(12.73) per share from the same period last year. The company reported quarterly sales of $1.86 million which beat the analyst consensus estimate of $322.75 thousand by 477.23 percent. This is a 92.26 percent increase over sales of $969.00 thousand the same period last year.
Dianthus Therapeutics Q2 EPS $(0.51) Beats $(0.55) Estimate, Sales $1.86M Beat $322.75K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated